Compared with the BPH rats, reductions in IL-8, TNF-α, DHT, MDA, and PCNA levels in both the prostate and serum and increases in SOD and caspase-3 were found, suggesting that XLQ might be an effective drug for BPH treatment. The gene discussed is SOD1; the disease is benign prostatic hyperplasia.